Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality8/10

Karyopharm Advances Selinexor Myelofibrosis sNDA Toward August Submission

Aug 13, 2026, 7:35 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Near-term regulatory catalyst (sNDA submission with possible Priority Review) plus positive SENTRY data can lift sentiment; however liquidity and debt obligations create downside risk, making the move modestly bullish with execution risk into 1–3 months.

AI summary

What happened, with direct paths to the underlying reporting

Karyopharm reported Q2 2026 results and reaffirmed plans to file an August sNDA for selinexor with ruxolitinib in myelofibrosis, potentially under Priority Review. Positive SENTRY data support SVR35 as a predictor of overall survival, with topline SENTRY-2 data expected in 2H-2026. The company maintains 2026 revenue guidance but faces near-term liquidity considerations due to debt obligations.

Q2 2026 total revenue $33.4M; down from $37.9M.
U.S. XPOVIO net product revenue $30.8M; royalty revenue $2.5M.
Planned August sNDA submission for selinexor + ruxolitinib in myelofibrosis.
Priority Review possible; SENTRY data bolster regulatory prospects.
2026 revenue guidance reaffirmed: total $130-150M; US $115-130M.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Karyopharm Advances Selinexor Myelofibrosis sNDA Toward August Submission

Karyopharm's SENTRY Trial Shows Promising Results for Myelofibrosis Treatment

These Analysts Revise Their Forecasts On Karyopharm Therapeutics After Q1 Results